Merus N.V. (MRUS)

53,18 -1,27 (-2,33%) In data: 03:23PM EDT. Mercato aperto.

Merus N.V.

Uppsalalaan 17
3rd & 4th floor
Utrecht 3584 CT
Netherlands
31 30 253 8800
https://www.merus.nl

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 172

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Sven Ante Lundberg M.D.	CEO, President & Executive Director	1,11M	N/D	1963
Mr. Gregory D. Perry	Chief Financial Officer	419,1k	N/D	1960
Mr. Peter B. Silverman J.D.	EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal	781,84k	565,02k	1978
Dr. Hui Liu Ph.D.	Chief Business Officer, Executive VP & Head of Merus U.S.	640,14k	1,8M	1967
Dr. Andrew Joe M.D.	Chief Medical Officer & Senior VP	685,12k	N/D	1967
Dr. Hennie Hoogenboom	Co-Founder and Scientific Advisor	N/D	N/D	N/D
Harry Shuman	Chief Accounting Officer	N/D	N/D	N/D
Mr. Cornelis Adriaan de Kruif Ph.D.	CTO & Executive VP	347,69k	N/D	1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.	Chief Scientific Officer & Senior VP	N/D	N/D	N/D
Kathleen Farren	IR & Corporate Communications Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Governance aziendale

L'ISS Governance QualityScore di Merus N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.